Interest of colchicine for the treatment of cystic fibrosis patients. Preliminary report.

Cystic fibrosis (CF) lung disease is characterized by persistent inflammation. Antiinflammatory drugs, such as corticosteroids and ibuprofen, have proved to slow the decline of pulmonary function although their use is limited because of frequent adverse events. We hypothesized that colchicine could be an alternative treatment because of its antiinflammatory properties and upregulatory effect on cystic fibrosis transmembrane regulator (CFTR) closely related proteins. We herein present results obtained in an open study of eight CF children treated with colchicine for at least 6 months. Clinical status was better in all patients and respiratory function tests significantly improved in five. Median duration of antibiotherapy decreased significantly. These preliminary results support our hypothesis of a beneficial effect of colchicine in CF patients and stress the need for a controlled therapeutic trial.

[1]  P. Linsdell,et al.  Glutathione permeability of CFTR. , 1998, American journal of physiology. Cell physiology.

[2]  S. Swensen,et al.  Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the Lung Study Group. , 1998, American journal of respiratory and critical care medicine.

[3]  E. Altschuler.  Azithromycin, the multidrug-resistant protein, and cystic fibrosis , 1998, The Lancet.

[4]  P. Linsdell,et al.  Adenosine Triphosphate–dependent Asymmetry of Anion Permeation in the Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channel , 1998, The Journal of general physiology.

[5]  G. Lenoir,et al.  Induction by antitumoral drugs of proteins that functionally complement CFTR: a novel therapy for cystic fibrosis? , 1997, The Lancet.

[6]  Y. Açil,et al.  Antiinflammatory and Antifibrotic Properties of Colchicine: Implications for Idiopathic Pulmonary Fibrosis , 1997, Lung.

[7]  M. Peters-Golden,et al.  Colchicine inhibits arachidonate release and 5-lipoxygenase action in alveolar macrophages. , 1996, The American journal of physiology.

[8]  R. Evers,et al.  The human multidrug resistance-associated protein functionally complements the yeast cadmium resistance factor 1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[9]  atrice Descamps-Latscha.  Inflammation in Cystic Fibrosis , 1996, Mediators of inflammation.

[10]  H. Veeze,et al.  Diagnosis of cystic fibrosis. , 1995, The Netherlands journal of medicine.

[11]  D. Riches,et al.  Early pulmonary inflammation in infants with cystic fibrosis. , 1995, American journal of respiratory and critical care medicine.

[12]  S. Peters,et al.  Effects of colchicine on IgE-mediated early and late airway reactions. , 1995, Chest.

[13]  P. J. Byard,et al.  Effect of high-dose ibuprofen in patients with cystic fibrosis. , 1995, The New England journal of medicine.

[14]  A. V. Eliseenkova,et al.  Colchicine‐resistance and enhancement of P‐glycoprotein activity after co‐cultivation of drug‐sensitive cells with multidrug resistant variants. , 1995, Cell biology international.

[15]  N. Høiby,et al.  Pathogenesis of cystic fibrosis , 1993, The Lancet.

[16]  C. Higgins,et al.  ABC transporters: from microorganisms to man. , 1992, Annual review of cell biology.

[17]  M. Spino,et al.  Colchicine: A State‐of‐the‐Art Review , 1991, Pharmacotherapy.

[18]  I. Pastan,et al.  Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. , 1987, The Journal of biological chemistry.

[19]  P. Fan,et al.  Mechanism of action of colchicine. V. Neutrophil adherence and phagocytosis in patients with acute gout treated with colchicine. , 1982, The Journal of pharmacology and experimental therapeutics.

[20]  L. Andrade,et al.  Effect of colchicine and heat shock on multidrug resistance gene and P-glycoprotein expression in rat liver. , 1994, Journal of hepatology.